Snibe launched MAGLUMI® SARS-CoV-2 Neutralizing Antibody

Release Date:2021-01-14

● MAGLUMI® SARS-CoV-2 Neutralizing Antibody Assay is available under CE Mark, a brand new solution supporting high-volume 

testing of SARS-CoV-2 neutralizing antibodies. 

● Cost-effective and large-scale solution for neutralizing antibody test- an important tool of the COVID-19 vaccine efficacy assessment. 

● 100% positive agreement to gold standard Virus Neutralization Test (VNT) ensures accurate results.*

● Additional COVID-19 testing solutions coming to market include MAGLUMI® SARS-CoV-2 Ag (CLIA) and MolecisionTM

SARS-CoV-2, Flu & RSV RT-PCR Assay.



Shenzhen, China, 30 December, 2020-Snibe announced that the MAGLUMI® SARS-CoV-2 Neutralizing Antibody Assay is available in CE accepting areas. The fully automatic MAGLUMI® SARS-CoV-2 Neutralizing Antibody Assay aims to detect neutralizing antibodies against the SARS-CoV-2, which indicate the immune status of the vaccine receivers and the COVID-19 patients.

Different from the traditional neutralizing antibody detection method-the plaque-reduction neutralization test (PRNT) which requires BSL-3 laboratories and may take up to 5 days to complete, MAGLUMI® SARS-CoV-2 Neutralizing Antibody are capable of providing the first result within 20 mins when combined with MAGLUMI® CLIA analyzers.  

Neutralizing antibodies reduce viral infectivity by binding to the surface epitopes of viral particles and blocking the entry of the virus to an infected cell, so it is critical to measure the presence of neutralizing antibodies quantitatively to assess the protective immune response after natural infection or vaccine injection.

Now the COVID-19 vaccine is moving closer to large-scale rollout worldwide, Snibe is proud to add the MAGLUMI® SARS-CoV-2 Neutralizing Antibody Assay in the comprehensive MAGLUMI® SARS-CoV-2 diagnostic portfolio, and help guide clinical decision making in the combat of the COVID-19.


* Quoted from the clinical sensitivity study in MAGLUMI® SARS-CoV-2 Neutralizing Antibody IFU.
▲Depending on samples and Assays configuration on MAGLUMI® X8 analyzer.


Related Product News:

1. Snibe received CE Mark for MAGLUMI® SARS-CoV-2 S-RBD IgG, a brand new solution for assessing the COVID-19 patients' immunity
2.The world's first 2019-nCoV (SARS-CoV-2) CLIA Kits received CE mark
3. Molecision SARS-CoV-2 RT-PCR Assay product features and benefits